Latest news with #2025JointCongress
Yahoo
04-06-2025
- Business
- Yahoo
'I Fell in Love with Ottawa and Never Left'
Local landscape architect to be honoured this week has no regrets after leaving the U.S. for Canada Jerrold Corush, OALA OTTAWA, Ontario, June 04, 2025 (GLOBE NEWSWIRE) -- This week in Ottawa, over 350 landscape architects from across Canada will gather to discuss the future of their profession. They will attend the 2025 Joint Congress of the Canadian Society of Landscape Architects (CSLA) and the Ontario Association of Landscape Architects (OALA), taking place from June 5 to 7 at the Rogers Centre. The theme of the event is 'Outside the Box: Rethinking Traditional Approaches in Landscape Architecture.' 'It invites landscape architects to rethink conventional approaches and explore bold, inclusive, and forward-thinking solutions to challenges like climate adaptation, urban densification, and the housing shortage,' said Aaron Hirota of Ottawa, the newly elected President of the OALA. 'It encourages reimagining our communities through creativity, equity, and sustainability.' At this year's Congress, 77-year-old Ottawa landscape architect Jerrold Corush will be honoured with the 2025 Pinnacle Award for Landscape Architectural Excellence. This award recognizes an OALA member for their outstanding professional achievements. It also helps raise awareness of landscape architecture among peers, clients, and the broader public. The OALA Awards take place on Thursday, June 5, at 7:30 p.m. To see the full list of award recipients, click here. Jerrold has also been welcomed as one of 12 new members of the CSLA College of Fellows in the category of Executed Works of Landscape Architecture. Being inducted is the highest recognition a member can receive, with only 292 members having received the FCSLA designation since its establishment. He is the founder and principal of CSW Landscape Architects Limited, which he established in 1975. Originally from Chicago, he brings professional experience from both the U.S. and Canada. He holds a Bachelor of Landscape Architecture and a Master's in Recreation and Park Planning from the University of Illinois. After visiting Canada, he 'fell in love with Ottawa' and decided to make it home. In the mid-1970s, he served on the OALA Council, helping the organization with its efforts to strengthen its presence across Ontario. Over the past five decades, he has built the firm into a respected and well-established practice in the Ottawa region. His work has shaped Ottawa's landscape and includes national, regional, and city parks, university campuses, transit systems, and major commercial/institutional projects. Some of his most notable projects include Ottawa-Carleton's original Transitway system, the U.S. Embassy, and the Royal Canadian Mint. 'One project I'm particularly proud of that resonates with people is the Rideau Canal Esplanade, which brought new life to that part of the city,' he said. Landscape architecture was founded as a profession nationally in 1934 and is now undergoing substantial changes, with practitioners working to strengthen their credentials with provincial governments across the country. 'Amid a U.S. trade war and the ongoing push for professional recognition in Canada, which has existed in the U.S. for decades,' said Jerrold Corush. 'This is a particularly interesting time to be a landscape architect with experience in both countries. We are a quiet profession, but we need to do more to show Canadians the impact we're having on key city-building and nation-building initiatives.' Eight other individuals and one organization will also be recognized on Thursday, June 5 at the OALA Awards Ceremony. They include: The OALA Honourary Member Award, recognizing non-landscape architects who have made a significant contribution to the profession: Diana Beresford-Kroeger of Ottawa, author and botanist Michael McClelland of Toronto, heritage architect David Stonehouse of Toronto, urban planner The OALA Public Practice Award, for exemplary service in public sector landscape architecture: Patrick Bunting of Ottawa The David Erb Memorial Award, for outstanding volunteer contributions to the Association and profession: Mark Hillmer of Toronto The OALA Award for Community Service to the Environment, for its commitment to public engagement and education on the importance of native plants and public green spaces: Canadensis Botanical Garden Society of Ottawa The Carl Borgstrom Award for Service to the Environment, for a career dedicated to environmental protection and sustainable design: Ian Dance of Richmond Hill The Jack Copeland Award for Intern Leadership and Contribution, for exceptional leadership and dedication as an OALA intern member: Steven Shuttle of Toronto The OALA Research and Innovation Award, for innovative work advancing the practice of landscape architecture: Patrick Li of Toronto For more information, please contact:Howard Brown, PresidentBrown & Cohen Communications & Public Affairshoward@ | 416-844-1180 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-03-2025
- Health
- Yahoo
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
–Sebetralstat enabled prompt treatment of laryngeal HAE attacks with median time of 1 hour and 16 minutes to onset of symptom relief– –Pooled data analysis showed adolescents treated with sebetralstat in median 4 minutes compared to over 3 hours in surveys – CAMBRIDGE, Mass. & SALISBURY, England, March 03, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. "The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack location, or severity," said Ben Palleiko, CEO of KalVista. "This is especially critical for vulnerable populations, such as those experiencing laryngeal attacks or adolescents whose only approved options are injectable on-demand treatments. Sebetralstat, if approved, would be the first oral on-demand treatment for HAE attacks, with the potential to address some of the most significant unmet needs in HAE and become the foundational therapy for HAE management." Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S was presented by Jonathan Bernstein, MD, FAAAAI, Professor of Clinical Medicine in the Department of Internal Medicine, Division of Allergy and Immunology at the University of Cincinnati College of Medicine; Partner at Bernstein Allergy Group and Clinical Research Center. 32 laryngeal attacks were treated with sebetralstat (September 14, 2024 cutoff) Median time to treatment with sebetralstat: 11.5 minutes after attack onset Median time to beginning of symptom relief: 1.27 hours 96% of those achieving beginning of symptom relief within 12 hours did so with a single dose No reports of difficulty swallowing film-coated tablet "Laryngeal attacks are often unpredictable and can progress rapidly, potentially leading to asphyxiation," said Dr. Bernstein. "Any attack involving the larynx must be considered a medical emergency and treated as quickly as possible after onset before symptoms worsen. Despite this, recent U.S. survey data showed the mean time to treatment for laryngeal attacks with injectable on-demand therapies was 2.5 hours. Patients in the KONFIDENT-S study treated their attacks with sebetralstat, with a median time to treatment of just under 12 minutes, followed by symptom relief with a median time of 1 hour and 16 minutes. These results show that in the time it takes many patients to decide whether to treat, prepare and administer an injectable on-demand treatment, most patients in KONFIDENT-S were already experiencing symptom relief. If approved, sebetralstat could represent a therapeutic advance over injectables." On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S was presented by Professor Danny Cohn, Head of the HAE clinic at Amsterdam University Medical Center (UMC), University of Amsterdam, Netherlands. 149 attacks were treated with sebetralstat across KONFIDENT/KONFIDENT-S (September 14, 2024 cutoff) Median time from attack onset to treatment: 4 minutes Safety and efficacy consistent with adults; no serious adverse events or adverse events leading to discontinuation "Adolescents face considerable challenges in treating their HAE attacks, with substantially longer delays to treatment than adults. This challenge is compounded in the U.S., where the only approved treatments options require either intravenous administration or subcutaneous administration by an HCP," said Dr. Cohn. "The pooled data from the KONFIDENT and KONFIDENT-S studies show that adolescents administered sebetralstat in a median of 4 minutes after attack onset, which compares favorably to a median of 3 hours and mean of 5.2 hours based on international survey data that was presented at AAAAI by Dr. Paula Busse titled, 'Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Adolescents'. Importantly, the safety and effectiveness of sebetralstat were consistent with what was observed in adults. The portability and ease of administration of sebetralstat, along with the elimination of injection-site reactions and associated anxiety, has the potential to bring transformative change to this underserved patient population." Links to all posters and presentations shared at AAAAI can be found on the KalVista website under Publications. About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older, with ongoing studies exploring its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Ryan BakerHead, Investor Relations(617) Molly CameronDirector, Corporate Communications(978) Sign in to access your portfolio
Yahoo
21-02-2025
- Health
- Yahoo
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England, February 21, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. The following poster presentations will take place on Friday, February 28, 2025, from 2:45–3:45 pm PT in the Convention Center, Ground Level, Hall A: Barriers to Timely On-demand Treatment of Hereditary Angioedema Attacks in Italian Patients (#180): Mauro Cancian, Paola Triggianese, Pietro Accardo, Francesco Arcoleo, Donatella Bignardi, Caterina Colangelo, Francesco Giardino, Antonio Gidaro, Marica Giliberti, Maria Domenica Guarino, Paola Lucia Minciullo, Stefania Nicola, Francesca Perego, Riccardo Senter, Giuseppe Spadaro, Massimo Triggiani, Sherry Danese, Julie Ulloa, Vibha Desai, Paul Audhya, Andrea Zanichelli. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Adolescents (#185): Mauro Cancian, Paula Busse, Tariq El-Shanawany, Maeve O'Connor, Sinisa Savic, Paola Triggianese, Patrick Yong, Andrea Zanichelli, Sherry Danese, Julie Ulloa, Vibha Desai, Paul Audhya, Sandra Christiansen. Delays in the On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported in Different Healthcare Systems (#187): Patrick Yong, Paula Busse, Timothy Craig, Tariq El-Shanawany, Padmalal Gurugama, Rashmi Jain, Maeve O'Connor, Cristine Radojicic, Sinisa Savic, James Wedner, Sherry Danese, Julie Ulloa, Vibha Desai, Paul Audhya, Sandra Christiansen. The following late-breaking poster presentations will take place on Saturday, March 1, 2025, from 9:45–10:45 am PT in the Convention Center, Ground Level, Hall A: Study to Adjudicate Hereditary Angioedema with Normal C1INH Diagnoses in the PIONEER-HAE Database (#L14): Maeve O'Connor, Dana Withrow, Scott Milligan, Vibha Desai, Paul Audhya, Marc Riedl. Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S (#L15): Jonathan Bernstein, Emel Aygoren-Pursun, Vesna Grivcheva-Panovska, Inmaculada Martinez-Saguer, Danny Cohn, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Christopher Yea, Utpaul Audhya, Henriette Farkas. The following oral presentation will take place on Saturday, March 1, 2025, from 2:25–2:35 pm PT in the Convention Center, Room 6C, Upper Level: On-demand Treatment Of Hereditary Angioedema Attacks With Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S (#552): Danny Cohn, Aharon Kessell, Tamar Kinaciyan, Rand Arnaout, Jonathan Peter, H. James Wedner, Emel Aygoren-Pursun, Jonathan Bernstein, Henriette Farkas, William Lumry, Marcus Maurer, Marc Riedl, Andrea Zanichelli, James Hao, Matthew Iverson, Michael Smith, Christopher Yea, Utpaul Audhya, Fotios Psarros. Links to all presentations can be found on the KalVista website under Publications. About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older, with ongoing studies exploring its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. View source version on Contacts Ryan BakerHead, Investor Relations(617) Molly CameronDirector, Corporate Communications(857)
